In a phase I trial, patients were vaccinated against the EBNA1 and LMP2 using the inactive fusion of those antigens (MVA-EL) in Chinese EBV-positive NPC patients [403]. The gene discussed is PSMB9; the disease is nasopharyngeal carcinoma.